Format

Send to

Choose Destination
Lancet Neurol. 2015 Jul;14(7):678-9. doi: 10.1016/S1474-4422(15)00094-0.

CHCHD2 and Parkinson's disease.

Author information

1
Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands; German Center for Neurodegenerative diseases, Tübingen, Germany.
2
Department of Molecular Neurosciences, Institute of Neurology, University College London, London, UK.
3
Sorbonne Université, Université Pierre et Marie Curie-Paris 06, Inserm, Centre National de la Reserche Scientifique, and Institute du Cerveau et de la Moelle épinière, Paris, France; Assistance Publique Hôpitaux de Paris, Hôpital de la Salpêtrière, Département de Génétique et Cytogénétique, Paris, France.
4
German Center for Neurodegenerative diseases, Tübingen, Germany; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
5
Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.
6
National Hospital for Neurology and Neurosurgery, University College London, London, UK.
7
Rita Lila Weston Institute, University College London, London, UK.
8
Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands; German Center for Neurodegenerative diseases, Tübingen, Germany; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
9
Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Silcherstraße 5, 70276, Germany. Electronic address: manu.sharma@uni-tuebingen.de.

Comment in

PMID:
26067110
DOI:
10.1016/S1474-4422(15)00094-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center